MOSCOW, 22 December 2021 / PRNewswire / –
- Preliminary study in the laboratory of the Gamaleya Center shows that Sputnik V demonstrates high viral neutralization activity (ANV) against Omicron (B.1.1.529) and should provide a strong defense against serious illness and hospitalization.
- The study was carried out using sera with a long period after vaccination (more than 6 months after vaccination) as an indicator of the long-lasting protection of Sputnik V.
- Sputnik V elicits a strong and long-lasting T cell response, and since 80% of the spike protein epitopes are unaffected by Omicron variant mutations, Sputnik V is expected to provide long-lasting protection against severe disease caused by Omicron. The long-lasting immunity of Sputnik V T lymphocytes contributes to 80% efficacy against Delta from 6 to 8 months.
- Sputnik Light as a booster significantly increases the virus neutralization activity against Omicron based on sera 2-3 months after revaccination. Virus neutralization activity against Omicron 2-3 months after Sputnik light amplifier in this preliminary laboratory study is higher than the ANV against wild type virus 6 months after the Sputnik V vaccination. Based on these data, the forecast the effectiveness of Sputnik V with the Sputnik Light booster against Omicron infection could be greater than 80%, because Sputnik V was shown to be more than 80% effective against wild-type virus 6 months after vaccination.
- 100% of individuals revaccinated with Sputnik Light as a booster developed neutralizing antibodies against Omicron and demonstrated their high level 2-3 months after revaccination.
- The Sputnik Light booster is expected to provide strong protection against infection, serious illness and hospitalization by Omicron. The Sputnik Light booster is recommended to increase the effectiveness of vaccines against Omicron. Boosting by Sputnik Light may enhance and prolong the rapidly declining efficacy of many vaccines in light of the combined Delta and Omicron challenge.
- Sputnik Light is a universal booster of other vaccines, including Sputnik V. In Argentina, a combination of Sputnik Light with other vaccines has been shown to be effective as a universal booster inducing a stronger antibody and T cell response compared to a homologous two-injection regimen.
- Sputnik V and Sputnik Light were developed on the basis of a safe and wTechnology well researched for over 30 years and has not been associated with rare serious side effects like myocarditis or pericarditis.
– The highest safety and efficacy of Sputnik V and Sputnik Light has been demonstrated in over 30 studies and actual data publications from over 10 countries.
Gamaleya National Epidemiology and Microbiology Research Center and Russian Direct Investment Fund (RDIF, that of Russia sovereign fund), investor in the Sputnik V and Sputnik Light vaccines, announced that an article “Sputnik Light booster after Sputnik V vaccination induces a robust neutralizing antibody response to the B.1.1.529 (Omicron) SARS-CoV variant -2 “was published in medRxiv (the preprint server for health sciences) and is available at:
The Gamaleya Center’s preliminary study demonstrated that the Sputnik V vaccine and the unique Sputnik Light booster (based on human adenovirus serotype 26, the first component of Sputnik V) are effective against the Omicron variant (B.1.1.529 ) from COVID, offering better protection compared to other vaccines. The heterologous booster with Sputnik Light is the solution to increase the effectiveness of other vaccines, including against Omicron, and to extend the protection period of the booster.
Sputnik Light as a booster significantly increases the neutralizing activity of the virus against Omicron based on sera 2-3 months after revaccination and is a universal booster for other vaccines inducing a stronger antibody and T cell response .
The Sputnik Light booster is recommended to increase the effectiveness of vaccines against Omicron. Sputnik Light stimulation as well as heterologous stimulation may enhance and prolong the rapidly declining efficacy of many vaccines in light of combined Delta and Omicron challenges.
Sputnik Light has already been registered in more than 25 countries as a stand-alone vaccine and as a universal booster for other vaccines helping to increase their efficacy (including in Argentina, United Arab Emirates, Bahrain, Philippines, and San Marino). Sputnik V has been licensed in 71 countries with a total population of over 4 billion people.
Sputnik Light has already shown strong results used as a booster in mix & match trials in Argentina. A combination of Sputnik Light with vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino, carried out in 5 provinces (City and Province of Buenos Aires, as well as in CÃ³rdoba, La Rioja and San Luis) demonstrated that Sputnik Light induces a stronger antibody and T lymphocyte response compared to the homologous regimen (two injections of the same vaccine). Each combination of ‘vaccine cocktail’ with Sputnik Light provided a higher antibody titre on day 14 after administration of a second dose compared to the original homogeneous regimens (same vaccine as the first and second dose. ) of each vaccine.
Efficacy data of Sputnik Light:
- Sputnik Light has been shown to be safe and very effective using real world vaccination data. In particular, data from the Ministry of Health of Buenos Aires (Argentina) demonstrated autonomous efficacy of Sputnik Light between 78.6 and 83.7% in the elderly (over 40,000 people aged 60 to 79), which is higher than that of many two-dose vaccines.
- Conclusions of the Gamaleya Center based on the data collected in Moscow demonstrated that the Sputnik Light vaccine administered alone is 70% effective against infection with the Delta variant of the coronavirus during the first three months after vaccination. The vaccine is 75% effective in people under 60 years of age. Sputnik V and Sputnik Light are based on a safe and effective human adenoviral vector platform and have not been associated with rare serious adverse events after vaccination, such as myocarditis or pericarditis.
SOURCE Russian Direct Investment Fund (RDIF)